Model-informed COVID-19 vaccine prioritization strategies by age and serostatus
Open accessPublished version of a preprint
The DOI matches its Crossref record; 59 of the 59 references it cites were found in a registry or an index.
Abstract
Limited initial supply of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) vaccine raises the question of how to prioritize available doses. We used a mathematical model to compare five age-stratified prioritization strategies. A highly effective transmission-blocking vaccine prioritized to adults ages 20 to 49 years minimized cumulative incidence, but mortality and years of life lost were minimized in most scenarios when the vaccine was prioritized to adults greater than 60 years old. Use of individual-level serological tests to redirect doses to seronegative individuals improved the marginal impact of each dose while potentially reducing existing inequities in COVID-19 impact. Although maximum impact prioritization strategies were broadly consistent across countries, transmission rates, vaccination rollout speeds, and estimates of naturally acquired immunity, this framework can be used to compare impacts of prioritization strategies across contexts.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Figures
![Fig. 1 Impacts of vaccine prioritization strategies on mortality and infections. (A) Distribution of vaccines for five prioritization strategies: under 20 years, adults 20 to 49 years, adults 20+ years, adults 60+ years, and all ages. (B, C, F, and G) Example simulation curves show [(B) and (C)] percentage of the total population infected over time and [(F) and (G)] cumulative mortality for no vaccines (gray dashed lines) and for five different prioritization strategies [colored lines matching (A)], with [(B) and (F)] 10% and [(C) and (G)] 30% vaccine supply. (D, E, H, and I) Summary curves show percent reductions in [(D) and (E)] infections and [(H) and (I)] deaths in comparison to an unmitigated outbreak for vaccine supplies between 1 and 50% after 365 days of simulation. Squares and diamonds show how the outputs from single simulations [(F) and (G)] correspond to points in summary curves (H). Gray shading indicates the period during which vaccine is being rolled out at 0.2% of total population per day. Black dots indicate break points at which prioritized demographic groups have been 70% vaccinated, after which vaccines are distributed without prioritization. These simulations assume contact patterns and demographics of the United States (38, 53) and an all-or-nothing, transmission-blocking vaccine with 90% vaccine efficacy and R0 = 1.5 (scenario 2) and R0 = 1.15 (scenario 1).](https://figures.cochat.ai/paper-figures/040af1c419fe4105805e757ba6eecdfa/model-informed-covid-19-vaccine-prioritization-strategies-by-age-and-serostatus-figure-1.jpg)
![Fig. 2 Mortality-minimizing vaccine prioritization strategies across reproductive numbers R0 and countries. (A to E) Heatmaps show the prioritization strategies that result in maximum reduction of mortality for varying values of [(A) and (B)] the basic reproductive number R0 and [(C), (D), and (E)] across nine countries, for vaccine supplies between 1 and 50% of the total population, for an all-or-nothing and transmission-blocking vaccine, 90% vaccine efficacy. [(A) and (B)] Contact patterns and demographics of the United States (38, 53). [(C), (D), and (E)] Contact patterns and demographics of POL, Poland; ZAF, South Africa; CHN, China; BRA, Brazil; ZWE, Zimbabwe; ESP, Spain; IND, India; USA, United States of America; and BEL, Belgium, with R0 and rollout speeds as indicated.](https://figures.cochat.ai/paper-figures/3232e6d2c98d4491b422e996e35f7beb/model-informed-covid-19-vaccine-prioritization-strategies-by-age-and-serostatus-figure-2.jpg)
![Fig. 3 Effects of age-dependent vaccine efficacy on the impacts of prioritization strategies. (A) Diagram of hypothetical age-dependent vaccine efficacy shows decrease from 90% baseline efficacy to 50% efficacy among individuals aged 80+ years, beginning at age 60 (dashed line). (B and C) Percent reduction in deaths in comparison with an unmitigated outbreak for transmission-blocking all-or-nothing vaccines with either constant 90% efficacy for all age groups (solid lines) or age-dependent efficacy shown in (A) (dashed lines), covering scenario 1 [0.2% rollout per day, R0 = 1.15; (B)] and scenario 2 [0.2% rollout per day, R0 = 1.5 (C)]. Black dots indicate break points at which prioritized demographic groups have been 70% vaccinated, after which vaccines are distributed without prioritization. Shown are contact patterns and demographics of the United States (38, 53); all-or-nothing and transmission-blocking vaccine.](https://figures.cochat.ai/paper-figures/85e54e74290b4a1b82ec5b49b5f8d03f/model-informed-covid-19-vaccine-prioritization-strategies-by-age-and-serostatus-figure-3.jpg)
![Fig. 4 Effects of existing seropositivity on the impacts of prioritization strategies. (A to C) Percent reductions in (A) infections, (B) deaths, and (C) years of life lost (YLL) for prioritization strategies when existing age-stratified seroprevalence is incorporated [August 2020 estimates for New York City; mean seroprevalence 26.9% (28)]. Plots show reductions for scenario 2 (0.2% rollout per day, R0 = 1.5) when vaccines are given to all individuals (solid lines) or to only seronegatives (dashed lines), inclusive of 96% serotest sensitivity, 99% specificity (54), and approximately 3 months of seroreversion (supplementary materials, materials and methods) (29). Shown are U.S. contact patterns and demographics (38, 53), all-or-nothing and transmission-blocking vaccine with 90% vaccine efficacy. Lower and higher seroprevalence examples are provided in figs. S12 and S13, respectively.](https://figures.cochat.ai/paper-figures/4122f4138dc44271af1ce6fd7d40abb0/model-informed-covid-19-vaccine-prioritization-strategies-by-age-and-serostatus-figure-4.jpg)
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Vaccination alone is not expected to be able to control the spread of the infection, and a carefully planned vaccination campaign25,26 needs to be coordinated with continued implementation of NPIs27 until sufficient coverage is reached to make the case fatality rate (CFR) similar to that of seasonal influenza.”
From Modeling vaccination rollouts, SARS-CoV-2 variants and the requirement for non-pharmaceutical interventions in Italy (2021) · cites this paper as [25]
Experimental — accuracy not yet measured
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Immunological memory to SARS-CoV-2 assessed for up to 8 months after infection.
Dan, J. M., Mateus, J., Kato, Y., Hastie, K. M., Yu, E. D., Faliti, C. E., Grifoni, A., Ramirez, S. I., Haupt, S., Frazier, A., et al. (2021) · Science · doi:10.1126/science.abf4063 · Cited by 2,656
COVID-19 and Racial/Ethnic Disparities
Webb Hooper, M., Nápoles, A. M., & Pérez-Stable, E. J. (2020) · JAMA · doi:10.1001/jama.2020.8598 · Cited by 2,047 · cited 1×
“However, other factors correlate with disease outcomes, such as treatment and healthcare access and comorbidities, which may correlate with factors like rural vs urban location, socioeconomic status, sex ( 41, 42 ), and race and ethnicity ( 43 ), that are not accounted for in this study.”
Age-dependent effects in the transmission and control of COVID-19 epidemics
Davies, N. G., Klepac, P., Liu, Y., Prem, K., Jit, M., CMMID COVID-19 working group, Pearson, C. A. B., Quilty, B. J., Kucharski, A. J., Gibbs, H., et al. (2020) · Nature Medicine · doi:10.1038/s41591-020-0962-9 · Cited by 1,759 · cited 1×
“Age-stratified susceptibility values were drawn from literature estimates ( 13 ).”
Sex differences in immune responses that underlie COVID-19 disease outcomes
Takahashi, T., Ellingson, M. K., Wong, P., Israelow, B., Lucas, C., Klein, J., Silva, J., Mao, T., Oh, J. E., Tokuyama, M., et al. (2020) · Nature · doi:10.1038/s41586-020-2700-3 · Cited by 1,459 · cited 1×
“However, other factors correlate with disease outcomes, such as treatment and healthcare access and comorbidities, which may correlate with factors like rural vs urban location, socioeconomic status, sex ( 41, 42 ), and race and ethnicity ( 43 ), that are not accounted for in this study.”
Why does COVID-19 disproportionately affect older people?
Mueller, A. L., McNamara, M. S., & Sinclair, D. A. (2020) · Aging · doi:10.18632/aging.103344 · Cited by 1,128 · cited 1×
“We evaluated the impact of vaccine prioritization strategies using an age-stratified SEIR model, because age has been shown to be an important correlate of susceptibility ( 12–14 ), seroprevalence ( 12,15 ), severity ( 16–18 ), and mortality ( 19,20 ).”
Changes in contact patterns shape the dynamics of the COVID-19 outbreak in China
Zhang, J., Litvinova, M., Liang, Y., Wang, Y., Wang, W., Zhao, S., Wu, Q., Merler, S., Viboud, C., Vespignani, A., et al. (2020) · Science · doi:10.1126/science.abb8001 · Cited by 1,107 · cited 1×
“We evaluated the impact of vaccine prioritization strategies using an age-stratified SEIR model, because age has been shown to be an important correlate of susceptibility ( 12–14 ), seroprevalence ( 12,15 ), severity ( 16–18 ), and mortality ( 19,20 ).”
The Efficacy of Influenza Vaccine in Elderly Persons: A Meta-Analysis and Review of the Literature
Gross, P. A., Hermogenes, A. W., Sacks, H. S., Lau, J., & Levandowski, R. A. (1995) · Annals of Internal Medicine · doi:10.7326/0003-4819-123-7-199510010-00008 · Cited by 1,100 · cited 1×
“COVID-19 vaccines may not be equally effective across age groups in preventing infection or transmission, a phenomenon known to affect influenza vaccines ( 23–26 ).”
Estimating the burden of SARS-CoV-2 in France
Salje, H., Tran Kiem, C., Lefrancq, N., Courtejoie, N., Bosetti, P., Paireau, J., Andronico, A., Hozé, N., Richet, J., Dubost, C.-L., et al. (2020) · Science · doi:10.1126/science.abc3517 · Cited by 1,038
Antibody Status and Incidence of SARS-CoV-2 Infection in Health Care Workers
Lumley, S. F., O’Donnell, D., Stoesser, N. E., Matthews, P. C., Howarth, A., Hatch, S. B., Marsden, B. D., Cox, S., James, T., Warren, F., et al. (2021) · New England Journal of Medicine · doi:10.1056/nejmoa2034545 · Cited by 940 · cited 2×
“Serostatus itself is an imperfect indicator of protection, and the relationship of prior infection, serostatus, and protection may change over time (10, 29,32,33).”
Govaert, T. M. E. (1994) · JAMA · doi:10.1001/jama.1994.03520210045030 · Cited by 867
Research works printed but not linked: 1
- K. E. Atkinson An Introduction to Numerical Analysis (Wiley 1989) chap. 2 pp. 56–58 second edn.
Cited by
Items 401–500 of 777
Miller, E. M., Law, E., Ajeen, R., Karasik, J., Mendoza, C., Abernathy, H., Garrett, H. E., King, E., Wallace, J., Zelek, M., et al. (2021) · PLoS ONE · doi:10.1371/journal.pone.0259070 · Cited by 6
“Premature easing may result in a rebound of cases [1] even in the presence of vaccines [3, 4], while extending restrictions may inflict irreversible damage to the economy and to children’s health and development [5, 6], especially in already distressed rural communities.”
BackgroundVaccination Schedule under Conditions of Limited Vaccine Production Rate
Książek, R., Kapłan, R., Gdowska, K. Z., & Łebkowski, P. (2022) · Vaccines · doi:10.3390/vaccines10010116 · Cited by 6
“[31] conducted a study using an age-stratified SEIR model to identify the age groups that should receive the highest priority in access to vaccination.”
MethodVaccination and three non-pharmaceutical interventions determine the dynamics of COVID-19 in the US
Zhong, L., Diagne, M. L., Wang, Q., & Gao, J. (2022) · Humanities and Social Sciences Communications · doi:10.1057/s41599-022-01142-3 · Cited by 6
An epidemic-economic model for COVID-19
Bai, J., Wang, X., & Wang, J. (2022) · Mathematical Biosciences & Engineering · doi:10.3934/mbe.2022449 · Cited by 6
Stocks, D., Nixon, E. J., Trickey, A., Homer, M., & Brooks‐Pollock, E. (2023) · Epidemics · doi:10.1016/j.epidem.2023.100716 · Cited by 6
Basciftci, B., Yu, X., & Shen, S. (2021) · SSRN Electronic Journal · doi:10.2139/ssrn.3799367 · Cited by 7
Emergent effects of contact tracing robustly stabilize outbreaksPreprint
Kotil, S. (2021) · medRxiv · doi:10.1101/2021.02.25.21252445 · Cited by 6
Addressing the COVID-19 Pandemic: Comparing Alternative Value Frameworks
Ferranna, M., Sevilla, J. P., & Bloom, D. (2021) · National Bureau of Economic Research · doi:10.3386/w28601 · Cited by 6
“…and being sensitive to the burden of COVID-19 impacts among socioeconomically vulnerable groups, most modeling exercises focus on strategies that maximize some health benefits, e.g., deaths averted or years of life lost averted (e.g., Bubar et al. 2021; Buckner et al. 2020; Rodríguez et al. 2020).”
BackgroundPre-vaccination testing could expand coverage of two-dose COVID vaccines
Pearson, C. A. B., Clifford, S., Pulliam, J. R. C., & Eggo, R. M. (2021) · Wellcome Open Research · doi:10.12688/wellcomeopenres.16835.1 · Cited by 5
A Year of COVID-19 Pandemic Roller-Coaster: The Malta Experience, Lessons Learnt, and the Future
Cuschieri, S., Grech, S., & Grech, V. (2022) · Disaster Medicine and Public Health Preparedness · doi:10.1017/dmp.2022.100 · Cited by 6
SARS-CoV-2 testing strategies for outbreak mitigation in vaccinated populations
Kumar, C. K., Balasubramanian, R., Ongarello, S., Carmona, S., & Laxminarayan, R. (2022) · PLoS ONE · doi:10.1371/journal.pone.0271103 · Cited by 5
Woodbine, M. J. H., Fernández-Niño, J. A., Rodríguez-Villamizar, L. A., & Rojas-Botero, M. L. (2024) · Public Health · doi:10.1016/j.puhe.2023.12.035 · Cited by 5
Preparing for pandemic response in the context of limited resources
Andrade, J., Beishuizen, B. H. H., Stein, M. L., Connolly, M. A., & Duggan, J. (2024) · System Dynamics Review · doi:10.1002/sdr.1775 · Cited by 5
Human behavior-driven epidemic surveillance in urban landscapes
Valgañón, P., Useche, A. F., Montes, F., Arenas, À., Soriano‐Paños, D., & Gómez‐Gardeñes, J. (2024) · npj Complexity · doi:10.1038/s44260-024-00021-z · Cited by 5
“In conclusion, our research highlights the importance of strategically leveraging human behavior data to design efficient control policies when facing an epidemic crisis 58 .”
Jang, G., Kim, J.-H., Thompson, R. N., & Lee, H. (2025) · Journal of Infection and Public Health · doi:10.1016/j.jiph.2025.102688 · Cited by 5
Impffortschritt in Deutschland und der Welt: Chancen und Risiken
Grimm, V., Lembcke, F. K., & Schwarz, M. (2021) · Wirtschaftsdienst · doi:10.1007/s10273-021-2894-5 · Cited by 5
“Die zukünftigen Inzidenzwerte dürften jedoch maßgeblich von der Impfquote unter (jüngeren) Menschen mit besonders vielen, auch generationenübergreifenden Kontakten abhängen (Wang et al., 2021b; Bubar et al., 2021).”
BackgroundNandakumar, V., Profaizer, T., Lozier, B. K., Elgort, M., Rychert, J. A., Slev, P. R., & Delgado, J. C. (2021) · The Journal of Applied Laboratory Medicine · doi:10.1093/jalm/jfab161 · Cited by 5
Contact tracing-induced Allee effect in disease dynamics
Arim, M., Herrera, D., Bermolen, P., Cabana, Á., Fariello, M. I., Lima, M., & Romero, H. (2022) · Journal of Theoretical Biology · doi:10.1016/j.jtbi.2022.111109 · Cited by 5
“Models may inform about the expected epidemic dynamic and the potential performance of alternative containment strategies (Bubar et al., 2021; Grantz et al. 2021; Moore et al., 2021; Yang et al., 2021) but are frequently limited by the sparsity of data (Fitzpatrick and Galvani, 2021).”
EFFECTS OF VACCINATION ON THE TRANSMISSION DYNAMICS OF COVID-19 IN DOUGHERTY COUNTY OF GEORGIA, USA
Pantha, B., Mohammed-Awel, J., & Vaidya, N. K. (2022) · Journal of Biological Systems · doi:10.1142/s021833902250019x · Cited by 5
Kinyili, M., Munyakazi, J. B., & Mukhtar, A. Y. A. (2023) · PLoS ONE · doi:10.1371/journal.pone.0264863 · Cited by 5
Greenland-Bews, C., Byrne, R. L., Owen, S. I., Watkins, R. L., Bengey, D., Buist, K., Clerkin, K., Escadafal, C., Finch, L. S., Gould, S., et al. (2023) · BMC Infectious Diseases · doi:10.1186/s12879-023-08033-1 · Cited by 5
“Model-based analysis has previously indicated that this strategy has potential to optimise the impact of a COVID vaccine dose (7,8).”
BackgroundGonzález‐Parra, G., Villanueva-Oller, J., Navarro-González, F. J., Ceberio, J., & Luebben, G. (2024) · Chaos Solitons & Fractals · doi:10.1016/j.chaos.2024.114695 · Cited by 5
WHO SAGE roadmap for prioritizing uses of COVID-19 vaccines in the context of limited supply
Omer, S. B., Faden, R., Kochhar, S., Kaslow, D., Pallas, S. W., Olayinka, F., Afolabi, M. O., Smith, P. G., & Wilder-Smith, A. (2020) · LSHTM Research Online (London School of Hygiene and Tropical Medicine) · Cited by 9
Penney, M. D., Yargic, Y., Smolin, L., Thommes, E. W., Anand, M., & Bauch, C. T. (2021) · PLoS ONE · doi:10.1371/journal.pone.0256889 · Cited by 5
Toward “hereditary epidemiology”: A temporal Boltzmann approach to COVID-19 fatality trends
Ukaj, N., Scheiner, S., & Hellmich, C. (2021) · Applied Physics Reviews · doi:10.1063/5.0062867 · Cited by 5
Bhattacharya, P., Machi, D., Chen, J., Hoops, S., Lewis, B. L., Mortveit, H., Venkatramanan, S., Wilson, M., Marathe, A., Porebski, P. J., et al. (2021) · IEEE International Conference on Big Data (BigData) · doi:10.1109/bigdata52589.2021.9671811 · Cited by 5
“For COVID-19, there have been multiple attempts at understanding the utility of age-and serostatus-based approaches [6], spatial heterogeneity [24], and global allocations [21].”
BackgroundThe Ethics of COVID-19 Vaccine Allocation: Don't Forget the Trade-Offs!
März, J. W., Molnár, A., Holm, S., & Schlander, M. (2022) · Public Health Ethics · doi:10.1093/phe/phac001 · Cited by 5
Modeling COVID-19 daily cases in Senegal using a generalized Waring regression model
Gning, L. D., Ndour, C., & Tchuenche, J. M. (2022) · Physica A Statistical Mechanics and its Applications · doi:10.1016/j.physa.2022.127245 · Cited by 5
Effects of infection fatality ratio and social contact matrices on vaccine prioritization strategies
Schulenburg, A., Cota, W., Costa, G. S., & Ferreira, S. C. (2022) · Chaos An Interdisciplinary Journal of Nonlinear Science · doi:10.1063/5.0096532 · Cited by 5
Safety and immunogenicity of inactivated SARS-CoV-2 vaccines in people with gastrointestinal cancer
Li, T., Song, R., Wang, J., Zhang, J., Cai, H., He, H., Hu, W., Yu, D., Wang, C., Pan, Q., et al. (2022) · International Journal of Infectious Diseases · doi:10.1016/j.ijid.2022.07.050 · Cited by 5
Optimizing Vaccine Allocation Strategies in Pandemic Outbreaks: An Optimal Control Approach
Tonkens, S., Klaver, P., & Salazar, M. (2022) · European Control Conference (ECC) · doi:10.23919/ecc55457.2022.9838180 · Cited by 6
Saliva-based SARS-CoV-2 serology using at-home collection kits returned via mail
Campbell, C., Roblin, D. W., Padmanabhan, N., Romero, D., Joe, J., Fathi, L., Whiting, T., Williamson, J. N., Goodwin, P., Mckie, C., et al. (2022) · Scientific Reports · doi:10.1038/s41598-022-17057-7 · Cited by 6
An alternative vaccine prioritization approach in response to COVID-19 pandemic
Sahinyazan, F. G., & Araz, Ö. M. (2022) · Journal of Humanitarian Logistics and Supply Chain Management · doi:10.1108/jhlscm-02-2022-0029 · Cited by 5
Salinas-Martínez, A. M., Vidales, E. P. R., Garza‐Carrillo, D., Robles‐Rodríguez, O. A., Montes‐de‐Oca‐Luna, R., & Marroquín-Escamilla, A. R. (2023) · Atención Primaria · doi:10.1016/j.aprim.2023.102606 · Cited by 5
Christensen, T., & Lægreid, P. (2023) · Administration & Society · doi:10.1177/00953997231167557 · Cited by 6
“There is a trade-off between prioritizing high-risk groups versus high transmission groups (Bubar et al., 2021).”
BackgroundTang, B., Liu, P., Yang, J., Wu, J., Yanni, X., & Tang, S. (2020) · medRxiv · doi:10.1101/2020.12.18.20248478 · Cited by 5
Level up for culture models - How 3D cell culture models benefit SARS-CoV-2 research
Häfner, S. J. (2021) · Biomedical Journal · doi:10.1016/j.bj.2021.02.001 · Cited by 5
“As a direct consequence, most countries have decided to start their vaccination programs against SARS-CoV-2 with the elderly, alongside the healthcare personnel and high-risk individuals [37].”
Evaluating and optimizing COVID-19 vaccination policies: a case study of SwedenPreprint
Sjödin, H., Rocklöv, J., & Britton, T. (2021) · medRxiv · doi:10.1101/2021.04.07.21255026 · Cited by 5
“211 Naturally infected individuals are thus assumed 100% protected (11).”
BackgroundQuantifying age-specific household contacts in Aotearoa New Zealand for infectious disease modelling
Sullivan, C., Senanayake, P., & Plank, M. J. (2024) · Royal Society Open Science · doi:10.1098/rsos.240550 · Cited by 4
Wende, D., Hertle, D., Schulte, C., Ballesteros, P., & Repschläger, U. (2021) · The European Journal of Health Economics · doi:10.1007/s10198-021-01408-8 · Cited by 4
“Although age is by far the most significant risk factor [3], until now, it has not been possible to establish whether younger people with severe lung diseases, for example, have significantly higher mortality risk than relatively healthy 75-year-olds, and should, therefore, be assigned higher priority [4].”
BackgroundOptimal vaccination ages for emerging infectious diseases under limited vaccine supply
Ai, M., & Wang, W. (2023) · Journal of Mathematical Biology · doi:10.1007/s00285-023-02030-3 · Cited by 4
“We follow Bubar et al. (2021) and Cruz-Pacheco et al. (2014) to minimize the effective reproduction number, which synthesizes the transmission risk and transmission duration.”
InfluentialKim, J., Matsunami, K., Ichida, Y., Okamura, K., Badr, S., & Sugiyama, H. (2024) · JOURNAL OF CHEMICAL ENGINEERING OF JAPAN · doi:10.1080/00219592.2024.2313318 · Cited by 4
Chen, C., Yang, M., Wang, Y., Jiang, D., Du, Y., Cao, K., Zhang, X., Wu, X., Chen, M., You, Y., et al. (2024) · iScience · doi:10.1016/j.isci.2024.109323 · Cited by 4
Jitsuk, N. C., Chadsuthi, S., & Modchang, C. (2024) · Heliyon · doi:10.1016/j.heliyon.2024.e28042 · Cited by 5
“where IFRi is the infection fatality ratio of infected individuals in age group i obtained from [15, 30].”
BackgroundMethodInfluentialGarduño-Orbe, B., Palma-Ramírez, P. S., López‐Ortiz, E., García-Morales, G., Sánchez-Rebolledo, J. M., Emigdio-Loeza, A., Gómez‐García, A., & López-Ortiz, G. (2025) · Infectious Disease Reports · doi:10.3390/idr17040074 · Cited by 4
“Regarding comorbidities, our results identified a higher prevalence of hypertension, diabetes, and obesity in the vaccinated group, consistent with the prioritization of these at-risk groups in vaccination programs [33].”
Modeling-Based Estimate of the Vaccination Rate, Lockdown Rules and COVID-19
Guo, C., & Chang, W. (2021) · Healthcare · doi:10.3390/healthcare9101245 · Cited by 4
“To simulate the dynamics of highly transmissible infectious diseases such as COVID-19, the most commonly used technique is SIR, SEIR, or SIRV compartmental modeling [7,8].”
MethodZhang, X., Song, Y., Tang, S., Xue, H., Chen, W., Qin, L., Jia, S., Shen, Y., Zhao, S., & Zhu, H. (2021) · Mathematical Biosciences & Engineering · doi:10.3934/mbe.2022001 · Cited by 4
Kobayashi, T., & Nishiura, H. (2022) · Mathematical Biosciences & Engineering · doi:10.3934/mbe.2022348 · Cited by 4
Kuechler, A. S., Weinhold, S., Boege, F., Adams, O., Müller, L., Babor, F., Bennstein, S. B., Pham, T.-X. U., Hejazi, M., Reusing, S. B., et al. (2022) · Vaccines · doi:10.3390/vaccines10071044 · Cited by 4
“Several types of vaccines were developed rapidly, but initially limited supply of doses mandated decisions on whom to vaccinate first [6].”
BackgroundGujjula, K. R., Gong, J., Segundo, B., & Ntaimo, L. (2022) · PLoS ONE · doi:10.1371/journal.pone.0270524 · Cited by 4
Optimal allocation strategies for prioritized geographical vaccination for Covid-19
Ghazal, I., Rachadi, A., & Hamid Ez-zahraouy, A. (2022) · Physica A Statistical Mechanics and its Applications · doi:10.1016/j.physa.2022.128166 · Cited by 4
“5 representing substantial virus growth in the case of COVID-19 [18].”
Sohaei, D., Ulndreaj, A., Mathew, A., Campbell, C., Stengelin, M. K., Sigal, G. B., Joe, J., Romero, D., Padmanabhan, N., Ren, A. H., et al. (2022) · The Journal of Applied Laboratory Medicine · doi:10.1093/jalm/jfac073 · Cited by 4
“When there is evident correlation between antibody levels and protection, serology can also be used to identify individuals at higher risk of reinfection and therefore inform vaccine prioritization strategies as needed (9).”
BackgroundAssessing the medical resources in COVID-19 based on evolutionary game
Guo, K., Lu, Y., Geng, Y., Lü, J., & Ши, Л. (2023) · PLoS ONE · doi:10.1371/journal.pone.0280067 · Cited by 5
“In almost all circumstances, reducing fatalities required distributing the vaccine to older adults who are most at risk of death [24].”
BackgroundGong, J., Gujjula, K. R., & Ntaimo, L. (2023) · Socio-Economic Planning Sciences · doi:10.1016/j.seps.2023.101547 · Cited by 4
“Deterministic approaches to evaluate the impact of vaccine efficacy, susceptibility, infectivity, and population variation on mortality, cumulative incidence, and years of life lost have been attempted [17].”
BackgroundQuantitative Theory of Viral-Immune Coevolution May Be within Reach
Mora, T., & Walczak, A. M. (2023) · PRX Life · doi:10.1103/prxlife.1.011001 · Cited by 5
Zou, Y., Lo, W.-C., Ming, W., & Yuan, H. (2024) · Infectious Disease Modelling · doi:10.1016/j.idm.2024.09.006 · Cited by 4
“While modelling approaches are commonly used to make predictions regarding vaccination (Bubar et al., 2021; Liu et al., 2022; Mahmud et al., 2022), most of these assume that vaccine protection declines at a constant rate to certain fi xed levels after the immunity has waned.”
MethodKitro, A., Tippong, D., Sirikul, W., Isaradech, N., Kosai, A., Saengoa, P., Thammasarot, J., Siviroj, P., Rungsiyakull, C., & Srithanaviboonchai, K. (2024) · American Journal of Infection Control · doi:10.1016/j.ajic.2024.10.005 · Cited by 4
A review of mathematical researches on the COVID-19 pandemic
Chen, Y., Pei, L., & Lei, Y. (2025) · International Journal of Dynamics and Control · doi:10.1007/s40435-024-01519-z · Cited by 4
“Building on it, Bubar et al. employed an age-stratified improved SEIR model to evaluate the effects of vaccine priority strategies on cumulative morbidity, mortality, and years of life lost [24].”
Impacto del suministro de vacunas contra COVID-19 sobre la letalidad por SARS-COV-2 en Colombia
Pinzón, J. E. D. (2021) · Revista Repertorio de Medicina y Cirugía · doi:10.31260/repertmedcir.01217372.1237 · Cited by 4
A Prototype of a Robot Capable of Tracking Anyone with a High Body Temperature in Crowded Areas
Chaari, M. Z., & Aljaberi, A. (2021) · International Journal of Online and Biomedical Engineering (iJOE) · doi:10.3991/ijoe.v17i11.25463 · Cited by 4
“In most countries, vaccine supplies are stratified by age, prioritizing the elderly at the most significant risk of dying from Covid-19 [11], [12].”
BackgroundAssortative mixing among vaccination groups and biased estimation of reproduction numbers
Klaus, C., Wascher, M., KhudaBukhsh, W. R., Tien, J. H., Rempała, G. A., & Kenah, E. (2022) · The Lancet Infectious Diseases · doi:10.1016/s1473-3099(22)00155-4 · Cited by 4
Cheng, Q., Collender, P. A., Heaney, A. K., McLoughlin, A., Yang, Y., Zhang, Y., Head, J. R., Dasan, R., Liang, S., Lv, Q., et al. (2022) · PLoS Computational Biology · doi:10.1371/journal.pcbi.1010575 · Cited by 4
“For instance, knowledge about the relative prevalence and virulence of pathogen subtypes is used to prioritize subtypes for vaccine or treatment development [11–13]; identify high-risk subpopulations to target with interventions [14]; and evaluate the risk of unintended consequences of interventions, such as serotype…”
BackgroundMathaha, T., Mafu, M., Mabikwa, O. V., Ndenda, J. P., Hillhouse, G., & Garcia, B. R. M. (2022) · Frontiers in Artificial Intelligence · doi:10.3389/frai.2022.1013010 · Cited by 5
“Although this has led to the identification of various COVID-19 vaccine candidates, the high and growing demand for the vaccine has become a challenge (Bubar et al., 2021).”
BackgroundPriority of Vaccination of the Population against COVID-19: Moral Principles
Rashi, T. (2023) · Vaccines · doi:10.3390/vaccines11020380 · Cited by 4
“[11], governments should follow a model-informed approach to vaccine prioritization that evaluates the impact of prioritization strategies on cumulative incidence and mortality.”
BackgroundGuo, Y., Ye, W., Zhao, Z., Guo, X., Song, W., Su, Y., Zhao, B., Ou, J., Deng, Y., & Chen, T. (2023) · Infectious Disease Modelling · doi:10.1016/j.idm.2023.02.002 · Cited by 4
“Additionally, corroborate the fi ndings in larger-scale modelling studies (Bubar et al., 2021; Monod et al., 2021) that the resurgence of COVID-19 was primarily driven by adults 20 e 49 years of age with highly effective transmission.”
Chisale, M., Sinyiza, F. W., Kaseka, P. U., Chimbatata, C. S., Mbakaya, B. C., Wu, T.-S. J., Nyambalo, B. W., Chauma-Mwale, A., Chilima, B., Yu, K.-L. J., et al. (2023) · Vaccines · doi:10.3390/vaccines11071185 · Cited by 4
“This also follows the finding from a modelling study that prioritising adults aged 60+ years in vaccination remains the best way to reduce morbidity and mortality, even if the SARS-CoV-2 serostatus is known [48].”
BackgroundPatón, M., Acuna, J. M., & Rodríguez, J. (2023) · Infectious Disease Modelling · doi:10.1016/j.idm.2023.07.012 · Cited by 6
Msuya, H. M., Mrisho, G. A., Mkopi, A., Mrisho, M., Lweno, O., Ali, A. M., Said, A. H., Mihayo, M., Mswata, S., Tumbo, A., et al. (2023) · American Journal of Tropical Medicine and Hygiene · doi:10.4269/ajtmh.23-0229 · Cited by 6
“…is implemented by 1) vaccinating directly those who are most vulnerable to severe outcomes and 2) protecting them indirectly by vaccinating those who are prone to transmitting the disease, 7,8 thereby making the current COVID-19 vaccines a viable option for reducing morbidity and mortality.”
Novel corona virus disease dynamical models with pulse vaccination
Li, C., & Lu, J. (2023) · Results in Physics · doi:10.1016/j.rinp.2023.107028 · Cited by 4
Hope, health and cure: the meanings of the vaccine against COVID-19
Melo, C. D. F., Ferreira, M. P. A., Costa, Í. M., Lins, S., & Eberhardt, A. C. (2023) · Psico-USF · doi:10.1590/1413-82712023280310 · Cited by 4
“…and efficacy (Bernal et al., 2021, Voysey et al., 2021), world authorities established a priority vaccination order, starting with those groups at risk, who would be the first to have contact with the vaccine in their body after the clinical trials (Bubar et al., 2021; MacIntyre et al., 2021).”
BackgroundElamin, M. Y., Maslamani, Y. A., ALSHEIKH, F., Sailah, M. A., Samm, M. A., Motanbk, A. M., Hejri, Y. M., Alameer, A. A., Khalid, O. H., Dahlan, A. A., et al. (2024) · Saudi Medical Journal · doi:10.15537/smj.2024.45.2.20230530 · Cited by 4
“30-32 Following our multivariate analysis of the factors associated with mortality and morbidity, the study’s findings highlight the importance of prior infection of COVID-19 in reducing the risk of severe outcomes and mortality among patients with COVID-19.”
BackgroundLives Saved from Age-Prioritized Covid-19 VaccinationPreprint
Goldstein, J. R., Cassidy, T., & Mahmud, A. S. (2021) · medRxiv · doi:10.1101/2021.03.19.21253991 · Cited by 4
Prioritizing Individuals Who Will Have Covid-19 Vaccine with Multi-Criteria Decision Making Methods
YAZICI, E., Üner, S. İ., Demir, A., DİNLER, S., & Alakaş, H. M. (2022) · GAZI UNIVERSITY JOURNAL OF SCIENCE · doi:10.35378/gujs.1053782 · Cited by 3
Chyzh, O. V. (2023) · The Journal of Politics · doi:10.1086/726933 · Cited by 3
“Unlike epidemiological studies that rely on aggregated population-level measures (e.g., Bubar et al. 2021), network 35.”
BackgroundDean, N. E., Halloran, M. E., & Zarnitsyna, V. I. (2024) · Vaccine · doi:10.1016/j.vaccine.2024.126516 · Cited by 3
Impact of COVID-19 Vaccination in Thailand: Averted Deaths and Severe Infections Across Age Groups
Wilasang, C., Suttirat, P., Wannigama, D. L., Amarasiri, M., Chadsuthi, S., & Modchang, C. (2024) · Tropical Medicine and Infectious Disease · doi:10.3390/tropicalmed9120286 · Cited by 4
“In this context, the development and deployment of vaccines emerged as a pivotal tool in epidemic control [8,9].”
Explanatory Particularism in Scientific Practice
Fagan, M. B. (2025) · doi:10.1093/9780191998874.001.0001 · Cited by 6
Why population heterogeneity matters for modelling infectious diseases
Harris, T., Richter, M., Alexander, P. C., Kitson, J., Tuccillo, J., Parikh, N., Germann, T. C., & Valle, S. Y. D. (2025) · Interface Focus · doi:10.1098/rsfs.2025.0006 · Cited by 3
SARS-CoV-2: Comparison of Active Immunity Acquired by Natural Exposure versus Inoculation of HCW
Shah, S. B., Chawla, R., & Mehta, A. (2021) · Galore International Journal of Health Sciences and Research · doi:10.52403/gijhsr.20210408 · Cited by 3
“[3] The goal of vaccination is to obtain protective levels of antibodies and if this purpose is met with a single dose of vaccine in COVID-survivors, then why not practice triage and vaccinate COVID-naïve individuals who are at greater risk of contracting COVID-19 by virtue of their”
BackgroundMixing age and risk groups for accessing COVID-19 vaccines: a modelling study
Wang, H., Ibuka, Y., & Nakamura, R. (2022) · BMJ Open · doi:10.1136/bmjopen-2022-061139 · Cited by 4
Modeling the effects of Prophylactic behaviors on the spread of SARS-CoV-2 in West Africa
Yedomonhan, E., Tovissodé, C. F., & Kakaï, R. G. (2023) · Mathematical Biosciences & Engineering · doi:10.3934/mbe.2023578 · Cited by 3
Equity considerations in COVID-19 vaccine allocation modelling: a methodological study
Rumpler, É., & Lipsitch, M. (2025) · Interface Focus · doi:10.1098/rsfs.2024.0037 · Cited by 4
Self-citationThe unequal effect of pandemics on aging and longevity: A health economic analysis
Strulik, H., & Grossmann, V. (2025) · Journal of Economic Behavior & Organization · doi:10.1016/j.jebo.2025.107263 · Cited by 3
Social inequalities in vaccine coverage and their effects on epidemic spreading
Manna, A., Karsai, M., & Perra, N. (2025) · PLoS Computational Biology · doi:10.1371/journal.pcbi.1013585 · Cited by 4
“In this context, incorporating socioeconomic factors (among others) in epidemic models, thus going beyond the traditional age-wise stratification, is essential to quantify the impact of vaccinations [35,44–51].”
Non-pharmaceutical interventions and inoculation rate shape SARS-CoV-2 vaccination campaign success
Galanti, M., Pei, S., Yamana, T. K., Angulo, F. J., Charos, A., Khan, F. L., Shea, K. M., Swerdlow, D. L., & Shaman, J. L. (2021) · Epidemiology and Infection · doi:10.1017/s095026882100217x · Cited by 4
“Increasing the uptake solely for the high-risk groups within the prescribed prioritisation order yielded the best outcome, consistent with other recent findings [25].”
ResultBurrowes, V. J., Usoro, I.-A., & Campbell, L. (2021) · Journal of Occupational and Environmental Medicine · doi:10.1097/jom.0000000000002265 · Cited by 3
Máscaras de tecido na prevenção da COVID-19: expectativa ou realidade?
Araruna, F. O. S., Moraes, M. B. C., Araruna, F. B., Luz, T. R. S. A., Serejo, A. P. M., do Amaral, F. M. M., & Coutinho, D. F. (2021) · Revista de Saúde Coletiva da UEFS · doi:10.13102/rscdauefs.v11i1.5929 · Cited by 9
Why we may need to rethink future SARS-CoV-2 vaccination strategies
Klimek, P. (2021) · The Lancet Regional Health - Europe · doi:10.1016/j.lanepe.2021.100214 · Cited by 3
“Nevertheless, an influential modelling study confirmed that for a wide range of assumptions, the optimal age-based strategy is prioritization of older people unless (i) vaccines would block transmissions with a probability of more than 80%, (ii) the vaccine would have very low efficacy for people aged >60y, or (iii) v…”
BackgroundThe medical resources allocation problem based on an improved SEIR model with sharing behavior
Li, W., Deng, L., & Wang, J. (2021) · Modern Physics Letters B · doi:10.1142/s0217984921505175 · Cited by 3
Sayed, T. M., Arshad, S. H., Aalam, M., Khan, F., & Majeed, S. (2021) · Pakistan Journal of Medical and Health Sciences · doi:10.53350/pjmhs211592789 · Cited by 3
Modeling Covid-19 Infection Cases and Vaccine in 5 Countries Highly Vaccinations
Abotaleb, M. S. A., Makarovskikh, T., Yonar, H., Mishra, P., Amr, B. A. D. R., Karakaya, K., & Yonar, A. (2021) · Turkish Journal of Mathematics and Computer Science · doi:10.47000/tjmcs.905508 · Cited by 3
“[5] made evaluations about priority vaccination with mathematical models.”
MethodOn the Road to Individualization of Vaccination: the Significance of Age and Sex
Каральник, Б. В. (2022) · Epidemiology and Vaccinal Prevention · doi:10.31631/2073-3046-2021-20-6-88-99 · Cited by 3
Vaccine Hesitancy, Vaccine Acceptance, and Recommendations about the COVID-19 Vaccines
Alexander, C. A., Wang, L., & Shah, V. (2021) · Research Review · doi:10.52845/jmrhs/2021-4-12-2 · Cited by 3
Kusuma, P. D., & Nugrahaeni, R. A. (2022) · Bulletin of Electrical Engineering and Informatics · doi:10.11591/eei.v11i2.3384 · Cited by 3
Chowdhury, D., Banerjee, S., Dey, A., Biswas, D., & Bhattacharyya, S. (2022) · Studies in computational intelligence · doi:10.1007/978-981-19-0489-9_9 · Cited by 3
Martignoni, M. M., Rahman, P., & Hurford, A. (2021) · AIMS Mathematics · doi:10.3934/math.2022220 · Cited by 3
Liu, L., Zhang, J., Li, Y., & Ren, X. (2022) · International Journal of Biomathematics · doi:10.1142/s1793524522500760 · Cited by 3
Matsushita, Y., Yokoyama, T., Hayakawa, K., Matsunaga, N., Ohtsu, H., Saito, S., Terada, M., Suzuki, S., Morioka, S., Kutsuna, S., et al. (2022) · Journal of Epidemiology · doi:10.2188/jea.je20220056 · Cited by 3
“22 In these prioritizations, for example, age and comorbidities are considered for treatment, and age, comorbidities, and occupation (eg, medical workers, essential workers) are considered for vaccination.”
Patón, M., Hosani, F. I. A., Stanciole, A. E., Aden, B., Timoshkin, A., Sadani, A., Najim, O., Cherian, C. A., Acuna, J. M., & Rodríguez, J. (2022) · Infectious Disease Modelling · doi:10.1016/j.idm.2022.08.003 · Cited by 3
“As described in other works, the impact of vaccination is indeed relevant in proportion to the entire population within the country (Bubar et al., 2021; Buckner et al., 2021; Hogan et al., 2021; Matrajt et al., 2021; Moghadas et al., 2021).”
Prioritizing vaccination based on analysis of community networks
Klise, K. A., Beyeler, W., Acquesta, E., Thelen, H. E., Makvandi, M., & Finley, P. D. (2022) · Applied Network Science · doi:10.1007/s41109-022-00522-7 · Cited by 3
Metadata
- Authors
- Bubar, K. M., Reinholt, K., Kissler, S. M., Lipsitch, M., Cobey, S., Grad, Y. H., & Larremore, D. B.
- Affiliations
- University of Colorado Boulder (US)
- Harvard University (US)
- University of Chicago (US)
- Corresponding author
- Bubar, Kate M.
- Larremore, Daniel B.
- ORCID
- Venue
- Science
- Published
- 2021-02-26
- Volume
- 371
- Issue
- 6532
- Pages
- 916-921
- ISSN
- 0036-8075 (ISSN-L)
- 1095-9203
- PMC
- PMC7963218
- OpenAlex
- W3123021790
- Cited by
- 775
- References
- 45
- Citations by year
- 2026: 32 · 2025: 56 · 2024: 87 · 2023: 109 · 2022: 222 · 2021: 261
- FWCI
- 65.62
- Type
- journal article
- Language
- en
- Open access
- hybrid
- doi.org
- Licence
- Locations
- Science (publishedVersion, cc-by)
- medRxiv (acceptedVersion, cc-by-nc-nd)
- PubMed Central (publishedVersion, cc-by)
- PubMed (publishedVersion)
- Knowledge@UChicago (University of Chicago) (submittedVersion, cc-by-nc-nd)
- PubMed Central (submittedVersion, cc-by-nc-nd)
- Informationszentrum Lebenswissenschaften (ZB MED) (submittedVersion, cc-by)
- ImmPort
- University of Chicago (cc-by)
- Funders
- National Institutes of Health (3U24GM132013-02S2)
- Morris-Singer Fund
- Topics
- Physical Sciences › Mathematics › Modeling and Simulation › COVID-19 epidemiological studies
- Health Sciences › Medicine › Infectious Diseases › SARS-CoV-2 and COVID-19 Research
- Social Sciences › Health › Vaccine Coverage and Hesitancy
- Keywords
- COVID-19 vaccine prioritization, SARS-CoV-2, serostatus, serological testing, transmission-blocking vaccine, vaccine inequity, cumulative incidence, mortality, years of life lost, naturally acquired immunity, vaccine supply
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.